Retatrutide Pharmacokinetics
Retatrutide Half-Life: What the Trial Data Actually Shows
Retatrutide has a half-life of approximately 6 days, as measured in the Phase 1b trial published in The Lancet (Urva et al., 2022). That single pharmacokinetic number explains almost everything about the dosing schedule: why injections happen once a week, why steady state at each dose level takes about 4 weeks (estimated from the ~6-day half-life), and why the drug lingers for about a month after your last dose. This guide covers all of it, drawing only from published trial data. For a more detailed look at how the half-life shapes your week-by-week protocol, see the retatrutide dosing guide half-life section.
Key Takeaways
- Retatrutide half-life is approximately 6 days as measured in the Phase 1b trial (Urva et al., Lancet 2022).
- By half-life arithmetic, about 97% of the drug is gone after 5 half-lives (30 days). In the washout calculator's model absorption adds about a day, and the level is under 3% of its peak by day 32 after the last dose.
- Steady state takes about 4 weeks of weekly dosing at each dose level (estimated from the ~6-day half-life), which is why the standard titration holds each dose for 4 weeks before escalating.
- Despite similar half-lives, retatrutide (6 days), tirzepatide (5 days), and semaglutide (7 days) all support once-weekly dosing.
- Use the GLP3Planner retatrutide calculator to model your personal plasma level curve based on dose and schedule.
Quick Answer
Retatrutide, often shortened to reta in patient and research communities, has a half-life of approximately 6 days (about 144 hours), as measured in the Phase 1b trial published in The Lancet (Urva et al., 2022). This enables once-weekly subcutaneous dosing. After stopping the drug, about 97% is gone after five half-lives (30 days by half-life arithmetic; day 32 in the washout calculator's model). Steady state takes about 4 weeks of weekly dosing at a given dose level, an estimate derived from the 6-day half-life (no trial has reported a measured figure). That trial tested doses from 0.5 mg up to 12 mg and reported dose-proportional pharmacokinetics, so the 6-day figure is not specific to one dose.
~6 days
Half-Life (Phase 1b, Lancet 2022)
~30 days
About 97% Gone (5 half-lives, arithmetic)
~4 weeks
Steady State Per Dose (Estimate)
Once Weekly
Dosing Interval
Investigational Status
Retatrutide is investigational and not FDA-approved as of October 2026. Lilly has reported Phase 3 TRIUMPH results and is reported to plan an FDA filing in early 2027. The half-life cited here was measured in the Phase 1b trial (Urva et al., Lancet 2022); the references below list every source. This guide is for educational purposes only. Talk to your doctor before making any treatment decisions.
What Is Retatrutide's Half-Life?
The half-life of a drug is the time it takes for plasma concentration to fall by 50%. For retatrutide, that number is approximately 6 days, or 144 hours, as measured in the Phase 1b trial published by Urva et al. in The Lancet in 2022. The trial abstract reports that the pharmacokinetics "were dose proportional and its half-life was approximately 6 days", and that they "suggest suitability for once-weekly dosing."
Dose-proportional pharmacokinetics means the drug's concentration in your bloodstream scales linearly with your dose. Doubling the dose roughly doubles the plasma level, which is a useful property for titration planning. It also means the 6-day half-life holds across the dose range the Phase 1b trial tested (0.5mg up to 12mg); you don't see a different half-life at lower or higher doses.
The "approximately 6 days" figure is the one the trial data support. Some sources cite "6 to 8 days," but this range comes from non-Tier-1 sources. The Phase 1b trial (Urva et al., 2022), the PMC review by Katsi et al. (2025), and the European Journal of Pharmacology paper by Abdul-Rahman et al. (2024) all confirm approximately 6 days. For a complete look at how this half-life shapes your protocol, the retatrutide dosing guide covers the titration logic in detail.
Why a 6-Day Half-Life Enables Once-Weekly Dosing
With a half-life of 6 days, a meaningful fraction of each dose is still circulating when the next injection is due. By half-life arithmetic, about 44% of a dose is left seven days later (one half-life elapses at day 6, so day 7 sits just past the halfway mark); in the calculator's model, which includes absorption, about 51% of the post-dose peak is left at day 7. Across repeated weekly doses the drug accumulates to a steady state, so the level never drops to zero before the next dose. This is exactly the pharmacokinetic profile a weekly medication needs.
Compare this to short-acting GLP-1 agents with half-lives of hours, which require daily or twice-daily dosing. Retatrutide's fatty-acid acylation chemistry (explained below) extends its residence in the bloodstream, making once-weekly subcutaneous injection viable. All three major weekly GLP-class agents sit in a similar half-life band, which is why all three use the same weekly injection schedule:
| Compound | Half-Life | Dosing Interval | FDA Status |
|---|---|---|---|
| Retatrutide | ~6 days | Once weekly | Investigational (Phase 3) |
| Tirzepatide (Mounjaro / Zepbound) | ~5 days | Once weekly | FDA approved |
| Semaglutide (Ozempic / Wegovy) | ~7 days | Once weekly | FDA approved |
No head-to-head pharmacokinetic trial has directly compared these three compounds. The figures above come from separate studies with different populations and designs. For a full clinical comparison, see the retatrutide vs tirzepatide guide.
How Retatrutide Achieves Its Long Half-Life
Retatrutide's extended half-life results from fatty-acid acylation, a chemical modification that allows the molecule to bind to albumin, the most abundant protein in blood plasma. Albumin acts as a reservoir and a shield: it slows renal filtration, protects the molecule from enzymatic degradation, and releases it slowly over time. This is the same core mechanism used to extend tirzepatide and semaglutide beyond the typical GLP-1 peptide half-life of minutes to hours.
The Abdul-Rahman et al. review (European Journal of Pharmacology, 2024) notes that the albumin-binding design "supports once-weekly subcutaneous administration" and that the long half-life is a key feature of the pharmacokinetic profile. The Katsi et al. review (PMC, 2025) confirms the mean half-life of approximately 6 days in the published trial data.
GLP-class half-lives compared: retatrutide (6 days), tirzepatide (5 days), semaglutide (7 days). All three support once-weekly dosing. Sources: the tirzepatide and semaglutide prescribing information and, for retatrutide, the Phase 1b trial (cross-study, not head-to-head).
How Long Does Retatrutide Stay In Your Body?
A common pharmacokinetic rule of thumb is that about 97% of a drug is gone after five half-lives (0.5^5 = 3.125% left). With a 6-day half-life, that is approximately 30 days of decay. Some drug remains after that; it is arithmetic, not a clinical threshold, and the model lands a day or two later because the last dose is still being absorbed after the injection. The drug does not disappear overnight, it follows an exponential decay curve, shedding roughly half its remaining concentration every 6 days.
| Days After the Peak | Approximate % Remaining | What This Means |
|---|---|---|
| Day 0 (peak) | 100% | Arithmetic starting point; in the model the peak comes a day or so after the last injection |
| Day 6 | ~50% | One half-life elapsed |
| Day 12 | ~25% | Two half-lives elapsed |
| Day 18 | ~12.5% | Three half-lives elapsed |
| Day 24 | ~6% | Four half-lives elapsed |
| Day 30 | ~3% (about 97% gone) | 5 half-lives; some drug remains |
To see the modelled dates for your own last injection, use the retatrutide washout calculator. Its days count from the last injection and land one or two days later than this table (under 3% by day 32), because the last dose is still being absorbed after you inject it. Enter your weekly dose, how many weeks you took it, and the date of your last dose to see when the modelled level falls to half, a quarter, and under 3%, and how much is left today.
Actual clearance varies by individual. Body composition, kidney function, and liver function all influence how quickly the drug processes. The 30-day figure is arithmetic (5 half-lives x 6 days), not a measured value or a guaranteed window for every person. If you need precise clearance timing before a procedure or medication switch, your doctor is the right call.
What Happens When You Stop Taking Retatrutide?
Drug levels fall over about a month after the last dose. Drug level alone does not tell you when retatrutide's effects on appetite and energy expenditure wear off; long-term discontinuation data are still emerging from the Phase 3 TRIUMPH trials.
The broader GLP-1 class literature, and the Phase 2 retatrutide data specifically, documents that weight regain is common after discontinuation. This is not a sign that the drug "stopped working." It reflects that the drug was doing the work, and without it, the underlying biology resumes. Phase 3 TRIUMPH trial data on long-term discontinuation effects are still emerging as of 2026.
"Retatrutide withdrawal" is a misnomer. The drug does not cause chemical dependence. Effects diminish because the drug clears, not because the body becomes dependent on it. If you're planning to stop, talk to your doctor first.
Track Your Retatrutide Levels
Model your personal plasma level curve, visualize steady state timing, and plan your dosing schedule with the free GLP3Planner calculator.
Model Your Retatrutide LevelsSteady State: When Does Retatrutide Start Working at Full Effect?
Steady state is the point where the amount of drug absorbed with each weekly injection equals the amount cleared between doses. At steady state, plasma levels stop climbing and stabilize at a consistent range. For retatrutide, this takes about 4 weeks of weekly dosing at a given dose level (estimated from the ~6-day half-life).
This is not arbitrary. It takes 4 to 5 half-lives for a drug to reach steady state, regardless of the compound. With a 6-day half-life, 4 half-lives = 24 days (roughly 3.5 weeks) and 5 half-lives = 30 days (roughly 4.5 weeks); in the calculator's model, which includes absorption, the level before the 5th weekly dose (day 28) is already 96% of steady state. The Phase 2 trial titration design, which held each dose for 4 weeks before escalating, was calibrated to let each dose reach steady state before increasing, not just for tolerability, but for pharmacokinetic completeness (Jastreboff et al., 2023).
Why Steady State Matters for Dosing Decisions
Escalating before steady state means stacking doses on top of drug levels that are still rising. The result is an unpredictable peak concentration at the new dose. This is not necessarily dangerous, but it makes it harder to attribute side effects or appetite changes to a specific dose level. The 4-week hold at each step gives the drug time to plateau before adding more.
This also means the drug level at any given dose keeps rising for about 4 weeks. Judging a dose's effectiveness before steady state leads to premature escalation. If you are on 4mg and wondering whether it is "working," the answer is: it depends when you started that dose. Before about week 4, you may not be seeing its full effect. See the retatrutide dosing schedule for the week-by-week calendar.
Steady State Timeline by Dose Level
| Dose | Week Started | Expected Steady State | Next Dose Level |
|---|---|---|---|
| 2mg | Week 1 | ~Week 4-5 | 4mg at Week 5 |
| 4mg | Week 5 | ~Week 9 | 8mg at Week 9 |
| 8mg | Week 9 | ~Week 13 | 12mg at Week 13 |
| 12mg | Week 13 | ~Week 17 | Maximum dose |
These timelines follow the standard published titration (2mg to 4mg to 8mg to 12mg, every 4 weeks) combined with the roughly 4-week time to steady state. Your doctor may adjust the pace based on tolerability. See the retatrutide dosage chart for the full titration arc.
Steady state timeline by dose level. Each dose takes about 4 weeks at that level before drug levels stabilize (estimated from the ~6-day half-life), which is why the standard titration holds each step for 4 weeks.
Retatrutide Half-Life vs Tirzepatide and Semaglutide
A common question: does the half-life difference between retatrutide, tirzepatide, and semaglutide actually matter? For dosing frequency, no. All three sit in the same pharmacokinetic tier (5 to 7 days) and all three use once-weekly subcutaneous injection. None requires a different schedule because of its specific half-life within that band.
The difference matters more for switching protocols and surgical washout planning. Tirzepatide at 5 days clears somewhat faster than semaglutide at 7 days, with retatrutide's 6-day half-life sitting between them. These figures are all cross-study, no head-to-head pharmacokinetic trial has compared these three agents directly.
For a detailed clinical comparison of mechanisms, weight loss outcomes, and FDA status, see the retatrutide vs tirzepatide comparison guide.
How to Use the Half-Life When Planning Your Dosing Schedule
The 6-day half-life has practical implications for three common scenarios: choosing an injection day, handling a missed dose, and planning for procedures.
Injection day choice. With a 6-day half-life, which day of the week you inject matters far less than doing it consistently. Seven days after a dose, around 44% of that dose's peak remains, and accumulation across weekly doses keeps steady-state levels high enough to stay pharmacologically active throughout the week. Pick a day that fits your routine and stick to it.
Missed dose. Retatrutide is investigational, so it has no FDA-approved label and no official instruction for a missed or late dose. What the 6-day half-life does tell you: levels fall gradually, so a dose taken a day or two late dips only a little below your usual low point, while a fully skipped week drops levels much further and takes a few weeks to rebuild. Never double-dose to make up for it. Trial participants should follow their protocol; if you're unsure, ask the doctor who knows your situation.
To see what the 6-day half-life does to your own levels after a skipped week or a late dose, use the retatrutide missed dose calculator. Enter your weekly dose and the week you missed to see the modelled drop and how many weeks recovery takes.
Before procedures. Retatrutide slows gastric emptying, and some anesthesiologists ask GLP-1 class users to hold their medication before general anesthesia. Your surgical team will set the specific hold period.
Use the Calculator
The GLP3Planner retatrutide calculator models each injection's absorption and elimination to plot your modelled drug-level curve. Enter your dose, injection day, and schedule to see how drug levels build, plateau at steady state, and decline after stopping.
Does the Half-Life Affect Microdosing Protocols?
Split-dosing (taking a weekly dose in two or more smaller sub-weekly injections) changes the trough-to-peak ratio and can soften side effects at higher dose levels. The 6-day half-life makes this work differently than it would with a shorter-acting compound. But it also shifts the pharmacokinetics in ways the standard titration wasn't designed for. Full coverage of protocols and rationale lives in the microdosing retatrutide guide.
Related Video: What Is the Half-Life of Retatrutide?
Regan Archibald breaks down the retatrutide half-life and why it matters for dosing. Published February 2026.
Frequently Asked Questions
What is the half-life of retatrutide?
Retatrutide has a half-life of approximately 6 days, as measured in the Phase 1b trial published in The Lancet (Urva et al., 2022). This means plasma concentrations fall by half every 6 days, enabling once-weekly subcutaneous dosing. Steady state at each dose level takes about 4 weeks, an estimate derived from the 6-day half-life (no trial has reported a measured figure).
How long does retatrutide stay in your body?
By half-life arithmetic, about 97% of retatrutide is gone after five half-lives of 6 days each (30 days); in the washout calculator's model, which includes absorption, the level is under 3% of its peak by day 32 after the last dose. Some remains after that. The approximately 6-day half-life was measured in the Phase 1b trial in type 2 diabetes (Urva et al., Lancet 2022), which tested doses from 0.5mg up to 12mg. The Phase 2 trial (Jastreboff et al., NEJM 2023) used maintenance doses of 1mg, 4mg, 8mg and 12mg.
What happens after you stop taking retatrutide?
Drug levels fall over about a month, but drug level alone does not tell you when retatrutide's effects on appetite, energy metabolism and weight wear off. Retatrutide is investigational; long-term discontinuation data are still emerging from Phase 3 TRIUMPH trials. If you're planning to stop, talk to your doctor before making any changes.
Does retatrutide increase metabolism?
Retatrutide acts as a triple agonist on GLP-1, GIP, and glucagon receptors. The glucagon receptor component influences energy expenditure and fatty acid oxidation. Phase 2 data showed substantial body weight reduction (up to 24.2% at 48 weeks on 12mg), partly attributed to this metabolic mechanism alongside appetite reduction.
Is 1mg of retatrutide enough?
The Phase 2 trial (Jastreboff et al., NEJM 2023) tested once-weekly maintenance doses of 1mg, 4mg, 8mg and 12mg; 1mg was the lowest, and that group started directly at 1mg. The standard published titration starts at 2mg, so 1mg is not part of it. Your doctor can advise on what's right for your specific situation.
Is 2mg of retatrutide too much to start?
No. 2mg is the lowest dose in the standard published titration: 2mg, then 4mg, then 8mg, then 12mg, each held for 4 weeks. In the Phase 2 trial, the 12mg group and one group each at 4mg and 8mg started at 2mg; other groups started at 1mg or 4mg. Gastrointestinal events were dose-related and were partially mitigated with a lower starting dose (2mg vs 4mg).
How much does retatrutide increase heart rate?
Phase 2 data (Jastreboff et al., NEJM 2023) showed mean pulse rate increases of approximately 3 to 5 beats per minute at higher doses, consistent with known GLP-1 receptor agonist pharmacology. The increase is dose-dependent and generally modest. If you have a pre-existing cardiac condition, talk to your doctor before starting.
Can retatrutide make you tired?
Fatigue is not among the most commonly reported side effects in the Phase 2 trial data. The most frequent adverse events were gastrointestinal: nausea, diarrhea, constipation, and vomiting. In the trial's posted results, nausea affected 45% of the 12mg group versus 11% on placebo. If fatigue occurs, it most likely ties to caloric restriction or GI effects, if it persists, check in with your doctor. See the retatrutide side effects guide for more detail.
Ready to Plan Your Retatrutide Protocol?
Join 675+ users modeling their GLP-class levels with the free pharmacokinetic calculator. Visualize steady state, clearance curves, and dose comparisons.
References
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5. PMID 36354040. [PubMed]
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. [NEJM full text]
- Katsi V, et al. Retatrutide, A Game Changer in Obesity Pharmacotherapy. PMC (NIH). 2025. PMC12190491. [PMC full text]
- Abdul-Rahman T, et al. Retatrutide's role in modern obesity and diabetes therapy. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2024.176969. [ScienceDirect]
- Pharmacy Times Editorial. Retatrutide Treatment Results in Reductions in Body Weight Compared to Placebo. Pharmacy Times. 2023-08-21. [Pharmacy Times]
- ClinicalTrials.gov. TRIUMPH Phase 3 Retatrutide Trials (NCT05929014 and related). U.S. National Library of Medicine. [ClinicalTrials.gov]
- ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Overweight (NCT04881760), posted results, adverse events. [ClinicalTrials.gov]
Medical Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice. Retatrutide is an investigational medication not approved by the FDA as of October 2026. Pharmacokinetic figures cited come from the published trials and literature listed in the references. Individual results and clearance times vary. Talk to your doctor before starting, stopping, or modifying any medication.
Related Retatrutide Articles
Retatrutide Dosing Guide
Full titration protocol from 2mg to 12mg, with half-life context for each dose step.
Retatrutide Dosing Schedule
Week-by-week injection calendar aligned with steady state timing at each dose level.
Microdosing Retatrutide
How the 6-day half-life shapes split-dosing protocols and tolerability strategies.
Retatrutide vs Tirzepatide
Half-life, mechanism, weight loss outcomes, and FDA status compared side by side.